Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix", "the Company") today announces that its prostate cancer PET[1] ...

Tursian Skincare officially launches, introducing a new benchmark in results-driven skincare. Backed by science, powered by precision formulation, and rooted in a deep respect for the skin's natural ...

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix", "the Company") today announces that its prostate cancer PET[1] ...

Novartis said on Monday that its targeted radiotherapy Pluvicto was shown to slow progression of a certain type of prostate ...

This is the web version of STAT’s special newslette r from the annual meeting of the American Society of Oncology. For more ...

Key growth drivers include increased healthcare spending, the rise of chronic diseases, and advancements in nanotechnology.

The B-cell inhibitors market is experiencing robust growth, driven by the rising prevalence of the addressable patient population, which incl ...

DelveInsight's "INBRIJA Market Size, Forecast, and Market Insight Report" highlights the details around INBRIJA, which consists of a dry powder formulation of levodopa for oral inhalation with the ...

Spun off from Novartis in 2019, Alcon is betting on new product launches to accelerate sales growth in the second half of ...

Growth is driven by the aging population, rising chronic diseases, and self-administration practices. Advances in technology, new product launches, and favorable policies bolster growth. Injectable ...